

British Neuro-Oncology Society Annual Meeting 2026

Local Therapies for Brain Cancers – Patient variability/ Emerging treatments / Optimising outcomes



Wednesday 1st – Friday 3rd July
University of Birmingham
Wednesday 1st July 2026

	Main Plenary Sessions – The Elgar Concert Hall	Location & Speaker
9:00 – 10:00	Registration, refreshments and exhibition	Aston Webb Great Hall
10:00 – 12:00	Session 1: Educational session: Rapid and ultra-rapid testing of brain tumours to meet patient clinical need	
10:05–10:15	Impact of waiting for a post operative diagnosis of brain tumour: The lived experience	
10:15–10:20	Free Paper 42: The case for rapid molecular diagnosis; The power of PPIE	Dr Simon Newman
10:21–10:29	Top Scoring Abstract 17: Psychological and holistic consequences of delays in molecular diagnosis after neuro-oncological surgery: a qualitative study	Mr Jay Kotecha
10:29–10:35	Q&A	
10:35–10:50	Validation of the single shared genomic platform across early adopter sites	Prof Matt Loose
10:51–10:56	Free Paper 50: Comparative evaluation of long- and short-read methylation-aware sequencing for CNS tumour diagnostics	Dr Simon Deacon
10:56–11:01	Free Paper 101: Independent replication and validation of nanopore-based long read sequencing and methylome classification for rapid brain tumour diagnosis	Dr Vassili Crispi
11:01–11:10	Q&A	
11:11–11:26	Integrating rapid diagnostic sequencing into the paediatric neuro-oncology workflow	
11:27–11:37	Free Paper 172: Transforming the National Genomic Test Directory to Improve Genomic Testing for CNS Tumours	Dr Jane Starczynski
11:38–11:48	Operational delivery of a networked local genomic platform within the NHS	Dr Victoria Wykes
11:48–12:00	Q&A Implementation	
12:00 – 13:00	Lunch and exhibition	Aston Webb Great Hall
13:00 – 13:05	Welcome to BNOS 2026	
13:05 – 15:30	Plenary Session 1	
13:05 – 13:25	Keynote Speaker: Window trials to improve drug development in Glioma	Prof Nader Sani
13:25–13:45	The need for Neuro-oncology Research Networks	Prof Colin Watts
13:45–14:15	Hot Topics	
13:46–13:54	tbcb	
13:55–14:04	Access to Clinical Trials for Brain Tumours (ACT-BT)	Prof Susan Short
14:05–15:00	Town Hall Trials Landscape Update	
14:05–14:10	Placebo for Diffuse Midline Glioma	Prof Catherine McBain
14:10–14:15	VIGOR- Adjuvant Varsidenib following RT and adjuvant chemo for grade 2 and grade 3 astrocytomas	Prof Catherine McBain
14:16–14:21	Portrait (PreOperative pRadlotherapy TTFields)	Dr Gerben Borst
14:22–14:27	COMBAT-GB: COMBination Nivolumab and ASTX727 (decitabine and cedazuridine) for treatment of primary Glioblastoma	Mr Puneet Plaha
14:28–14:33	Recurrent-GB: Repeat Excision Upon Recurrence: Rethinking Neurosurgical Treatment of Glioblastoma	Mr Puneet Plaha

	Parallel Sessions – Aston Webb C Block Lecture Theatre	Location Speaker
9:00 – 10:00	Registration, refreshments and exhibition	Aston Webb Great Hall
10:00 – 11:25	Parallel Session 1: Education Session: AHP	Location Speaker
10:00–10:05	Welcome	
	Management of Low Grade Glioma	
10:10–10:15	Long term health outcomes in oligodendrogliomas	Dr Florian Boele
10:16–10:26	Integrated Low Grade Glioma Care	Kelly Dawson
10:27–10:37	A dedicated low grade glioma clinic: a holistic, patient centred approach	Charlotte Robinson
10:37–10:42	Free Paper 59: Early psychosocial support after a brain tumour diagnosis: a collaborative model between Southmead Hospital and Brain Tumour Support	Dr Lucy Wilkinson
10:42–10:55	Q&A + Discussion	
10:55–11:00	Prehabilitation	
11:00–11:05	Free Paper 54: Access to Prehabilitation in UK Neuro-Oncology: Insights from a UK-wide review of adult brain tumour services (2024–2026)	Ms Sara Melhuish
11:06–11:11	Free Paper 89: Referral Patterns, Interventions and Outcomes: A 12 month Retrospective Review of Allied Health Professional Referrals from a Late Effects Clinic.	Mrs Paula Shukla
11:12–11:22	AHP service: Improving Patient Experience	Gary Walsh & Anne Jammes
11:23–11:33	TBC	Kim Grove
11:34–11:44	Prehabilitation in Cardiff	Cathryn Lewis
11:44–12:00	Q&A + Discussion	
12:00 – 13:00	Lunch and exhibition	Aston Webb Great Hall
15:00–15:30	Refreshments and exhibition	Aston Webb Great Hall
15:30–16:50	Parallel Session 2: AHP: Survivorship and quality of life	
15:30–15:35	Free paper 57: The role of the Clinical Nurse Specialist in neuro-oncology: Insights from a UK-wide review of adult brain tumour services (2020–2026)	Andrew Wright
15:36–15:41	Free paper 22: Quality of life and services use in patients diagnosed with brain tumours: data from a national cancer survivorship study	Ms Kerlann Le Calvez
15:42–15:47	Free paper 15: Promoting the need for a dedicated Neuro-Oncology Occupational Therapy Service at QEHB: A Quality Improvement Project	Miss Megan Jones
15:48–15:53	Free Paper 37: Outcomes of a National Specialist Counselling Service for People Affected by Brain Tumours	Jen Boilestad
15:54–15:59	Free Paper 90: Developing Patient-Focused Outcomes for Routine Clinical Care in Glioma: A Synthesis of Qualitative Evidence from the COMBaT Study.	Dr Stephanie Sivell
16:00–16:05	Free Paper 167: Improving safe delivery of steroids and side effect management in brain tumour patients.	Dr Louise Dullea
16:05–16:15	Q&A	

14:34-14:39	CARE study: Phase 2 open-label study: Repotrectinib in paediatric and young adult patients with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations.	Dr Elwira Szycho
14:40-14:50	Paediatric Medulloblastoma trials including MB6	Dr Jenny Adamski
14:51-14:56	EORTC Portfolio Update pre recorded	Dr Emilie LeRhun
14:56-15:00	Final Trial Summary Slides	
15:00-15:30	Refreshments and exhibitor	Aston Webb Great Hall
15:30-17:30	Session 2: Glioma: Optimising Radiotherapies	
15:30-15:55	Keynote Speaker: Improving tumour control and reducing neurotoxicity by Prof Anthony Chalmers combining radiotherapy with inhibitors of the DNA damage response	
15:55-16:15	Investigating targeted radiotherapies for the effective treatment of glioblastoma	Prof Jason Parsons
16:15-16:25	Top Scoring Abstract 156: Multidisciplinary decision-making in the management of recurrent glioblastoma – a multi-centre UK questionnaire study.	Mr Chris McKinnon
16:26-16:33	Free Paper 31: CD44-Gal9 Interaction between IDH1-mutant Grade 4 Astrocytoma and Microglia Promotes Invasion and Proliferation of Tumor Cells	M.Sc Nathalie Große
16:34-16:41	Free Paper 117: Transcript-resolved mapping of the m6A RNA modification landscape in glioma using nanopore direct RNA sequencing	Dr Simon Deacon
16:42-16:49	Free Paper 136: Tessa Jowell BRAIN MATRIX interim analysis: surgical and oncology outcomes in glioblastoma patients	Dr Vassili Crispi
16:50-16:55	Power Pitch 122: Surgical Outcomes for High Grade Glioma in Patients Aged 70 Years and Older: A 10 Year Single Centre Cohort Study	Mr Hazem Eid
16:56-17:01	Power Pitch 68: Adjuvant chemotherapy in WHO Grade 2 Astrocytoma: Retrospective Analysis at NNUH to Inform a Multicentre Comparative Study	Dr Clare Hannon
17:01-17:31	Platinum Sponsored talk	Novocure
17:31	Close of session	
17:30 - 19:00	Welcome Networking & Poster Reception	Aston Webb Great Hall
17:30 - 19:00	The Birmingham Boron Neutron Capture Therapy Facility timed visits	University of Birmingham
18:10-18:51	Power Pitch Session – Lecture Theatre G33	University of Birmingham
18:10-18:15	148: Using real-world data from GlioCova to assess the feasibility and revise the design of the ARISTOCRAT trial in recurrent glioblastoma	Dr Josh Savage
18:16-18:21	165: Astrocyte–Glioblastoma Metabolic Interactions at the Invasive Margin Reveal Therapeutic Vulnerabilities	Ms Une Kontrimaite
18:22-18:27	58: Disrupting metabolic plasticity in glioblastoma stem-like cells via FABP7 inhibition and DHA supplementation	Ms Cécilia Bernier
18:28-18:33	79: Diagnostic Utility of DNA Methylation Profiling in CNS Tumors: A Comparative Study of FFPE and Fresh-Frozen Tissues	Dr. Jyotsna Singh
18:34-18:39	98: Barriers and opportunities in the integrated histopathological-molecular diagnosis of adult diffuse gliomas: a national survey of neuropathology units in UK&I	Dr Vassili Crispi
18:40-18:45	74: Development and evaluation of a personalised prognostic prediction model for overall survival in patients with glioblastoma using machine-learning methods.	Miss Alina Morozova
18:46-18:51	55: Radiotherapy Peer Review in Neuro-Oncology: National Survey of Practice, Barriers and AI Integration	Dr Sarah Kingdon

	Parallel Sessions – Aston Webb C Block Lecture Theatre	Location Speaker
16:15-16:55	AHP Career Development workshop	Chairs: Shivani Shoni, Rhona Watson, Mitchell Hickman
16:15-16:25	What TJBCM offers to AHPs to support their career and research skill development	TJBCM Dr Nicky Huskens
16:25-16:35	Deep dive into AHP Research Fellowship programme including key tips, tricks and pitfalls to avoid to become more research-active	TJBCM Camille Goetz
16:35-16:45	Co-designing a framework to guide individualisation of radiotherapy education and information resources for patients and caregivers affected by glioblastoma	TJBCM AHP Research Fellow Sharon Fernandez
16:45-16:55	Q&A	
17:30	Close of session	
17:30 – 18:30	BNOS Mentor and Mentee meet up	Aston Webb Hall
17:30 – 19:00	Poster & Networking welcome reception	Aston Webb Great Hall
17:30 – 19:00	The Birmingham Boron Neutron Capture Therapy Facility timed visits	University of Birmingham

	Main Plenary Sessions – The Elgar Concert Hall	Location Speaker
7:00	BNOS 5K Run	
8:00–09:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:30	Session 3: Preclinical models of brain tumour	
9:00 – 9:20	Keynote speaker: Predictive patient–derived glioma organoid models for functional precision neuro–oncology	Prof Haikun Liu
9:20–9:35	Design and development of Chemoseed for local brain tumour drug delivery	Prof Chris McConville
9:35–9:50	From single–cell omics to patient derived cells: dissecting and modeling glioblastoma heterogeneity	Prof Sara Piccirillo
9:50–10:00	Q&A and discussion	
10:00–10:10	Top scoring abstract 41: Pharmacological depletion of NAD ⁺ has single agent cytotoxicity and radiosensitises glioma stem–like cells through impaired DNA replication and repair.	Professor Anthony Chalmers
10:11–10:18	Free paper 129: Electroactive drug delivery for local glioblastoma treatment	Mr Joshua Killilea
10:19–10:26	Free Paper 5: A multivariate plasma biomarker model enabling safe exclusion of glioblastoma	M. Jonathan Decarpentrie
10:32 – 11:00	Refreshments and exhibiton	Aston Webb Great Hall
11:00–11:30	Plenary Session 2: Updates in Vorasidenib	
11:00–11:15	Free paper 137 & 138: Phase 3 INDIGO trial of vorasidenib versus placebo: updated efficacy, safety and exploratory analysis of seizures and quality of life	Prof Cath McBain
11:15–11:22	Free paper 35: Access to Vorasidenib for Low–Grade Glioma in the UK: Voices of Patients, Carers and Clinicians	Rachel Roberts
11:23–11:30	Free Paper 102: Real–world Use of Vorasidenib in Adult IDH1/2–Mutant Low–Grade Glioma Across UK NHS Trusts	Mr Abraham Sondhi
11:31–11:38	Free paper 145: Implementing Vorasidenib in Clinical Practice: A Single–Centre Real–World Service Evaluation	Dr Brooke Smart
11:38–12:08	Platinum Sponsored talk	Servier
12:09–12:20	Brain Tumour Research Young Investigator Award	
12:20–12:30	BNOS Conference photo	
12:30 – 13:30	Lunch and exhibition	Aston Webb Great Hall
13:30–15:00	Plenary Session 3: Mapping Neuro–oncology to National Strategy	
13:30 – 13:50	Keynote Speaker: Overview of the National Cancer plan	Mr David Fitzgerald
13:50 – 14:05	Analogue to digital implications for clinical trials	Prof Amos Burke
14:05 – 14:20	Hospital to community care: The West Midlands perspective	Dr Sonia Ashraf
14:20–14:35	National Strategies– turning promise into practice	Cameron Miller
14:35–15:00	Panel discussion	
15:00 – 15:30	Refreshments and exhibiton	Aston Webb Great Hall

	Parallel Sessions – Aston Webb C Block Lecture Theatre	Location Speaker
7:00	BNOS 5K Run	
8:00–9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:30	Session 3: Parallel Session Paediatric and TYA	
09:00–09:25	Keynote speaker: Updates on CNS germinoma: the MonoGerm trial and utility of CSF miR–371a–3p	Prof Matt Murray
09:26–09:36	Top Scoring Abstract 109: Multi–omic integration reveals intra–tumour heterogeneity and identifies disulfiram and copper as a synergistic therapy in paediatric ependymoma	Dr. Alina Pandele
09:37–09:44	Free Paper 142: Arginine deprivation improves survival and activates the immune system in mouse models of diffuse midline glioma.	Molly Brooks
09:45–09:52	Free Paper 152: Re–irradiation for recurrent paediatric diffuse midline glioma: an international, multi–institutional retrospective study.	Dr Helen Benghiat
09:53–10:00	Free Paper 11: Single–nucleus and spatially resolved multi–omics uncover intracranial germinomas’ microenvironment and associated molecular features	Professor Ho–Keung Ng
10:01–10:08	Free Paper 103: A Medulloblastoma brain slice culture radiotherapy platform to dually assess therapeutic efficacy and toxic	Miss Kristy Kehoe
10:09–10:16	Free Paper 147: Cutting the power: targeting what fuels aggressive brain cancer	Dr Katherine Eales
10:17–10:24	Free Paper 119: Developing a Teenage and Young Adult Brain Tumour Standard Operating Procedure in a UK Tertiary Neurosciences Centre	Miss Aimee Goel
10:25–10:30	Power Pitch 118: Molecular and Immunological Landscape of the Pleomorphic Xanthoastrocytoma–Epithelioid Glioblastoma Spectrum	Dr. Iman Dandapath
10:30 – 11:00	Refreshments and exhibiton	Aston Webb Great Hall
12:30 – 13:30	Lunch and exhibition	Aston Webb Great Hall
15:00 – 15:30	Refreshments and exhibiton	Aston Webb Great Hall
15:30–17:30	Session 4: Parallel session: Imaging	
15:30–15:45	Gold sponsor talk: Brain Lab	Aston Webb C Block Lecture Theatre
15:46– 16:11	AI assessments of brain Tumours	Dr Tom Booth
16:11 – 16:26	Predicting sites of tumour progression in the invasive margin of glioblastomas (PRaM–GBM Study): a multicentre imaging study	Prof Stephen Price
16:27 – 16:37	Top Scoring abstract 24: Human–AI collaboration in brain tumour assessments improves both human and AI agent performance	Dr James Ruffle
16:38 – 16:45	Free paper 88: Slip Interface Imaging in Glioblastoma: A Pilot Study of Tumour–Brain Adhesion and Surgical Resectability	Dr Lucy Hiscox
16:46 – 16:53	Free Paper 80: The Multi–Modal Combination of Magnetic Resonance Spectroscopy and Apparent Diffusion Coefficient Features Improves Radiological Prognostic Stratification of Paediatric Medulloblastoma	Mr Timothy Mulvany
16:54 – 17:01	Free Paper 60: Persistent minimal contrast enhancement following autologous stem cell transplantation in primary CNS lymphoma	Miss Ellie–May Bond
17:02 – 17:07	Power Pitch 108: Interpretable Radiomics–Based Prediction of IDH Status in Glioma	Dr Abdulkirim Duman

15:30–17:30	Session 4: Metastasis and other CNS tumours	
15:30 – 15:50	Keynote Speaker: The Cancer Neuroscience of Brain Metastases: Emerging concepts and novel therapeutic targets*	Dr Matthia Karreman
15:50–16:10	Leptomeningeal metastasis: translational research and future directions	Dr Amanda Fitzpatrick
16:10–16:25	Debate/ Q&A	
16:26–16:36	Top Scoring Abstract 46: Anti-tumour immune responses in melanoma brain metastases require cDC1 population and the extracranial tumour	Dr Dario Guglietta
16:37–16:44	Free Paper 76: Metabolic heterogeneity in Brain Tumours: Distinguishing brain metastases from glioblastomas	Ms Ishana Rajgopal
16:45–16:52	Free Paper 94: Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis.	Dr Harriet Hebbes
16:53–17:00	Free paper 82: Proton versus photon stereotactic radiotherapy for brain metastases unsuitable for single-fraction stereotactic radiosurgery: a dosimetric comparison with robustness analysis	Dr Vanita Gandhi
17:01–17:08	Free Paper 77: Outcomes Following Stereotactic Radiosurgery for Brain Metastases from Lung Adenocarcinoma: The Wessex Experience	Dr Arda Karakaya
17:09–17:16	Free Paper 9: Development of a Rapid Lateral Flow Assay for Early Identification of Glioblastoma and Brain Metastases Using a Circulating Serum Biomarker	Ms Carys Jordan
17:17–17:24	Free Paper 21: Adult ependymoma in England: Incidence, treatment, and outcomes from GlioCova	Ms Kerlann Le Calvez Imperial
17:30	Close of session	
17:30–18:00	BNOS AGM	Elgar Concert Hall
19:30 – 23:00	Conference Dinner	Council House, Birmingham

17:08 – 17:13	Power Pitch 120: Updates on Magnetic Resonance Imaging assessment of tumour MicroStructure in Glioblastoma: A cross-sectional study (The MIMOSA Study)	Dr Jennifer Golten
17:14 – 17:19	Power Pitch 56: The evolving challenges and opportunities in adult brain tumour imaging: Insights from a review of United Kingdom neuro-oncology centres (2021–2024)	Prof Adam Waldman
17:20 – 17:25	Power Pitch 25: Imaging Tumour-Associated Macrophages in Gliomas and Vestibular Schwannomas Using Ferumoxytol-Enhanced MRI	Mr James Breese
17:30	Close of session	
19:30 – 23:00	Conference Dinner	Council House, Birmingham

	Main Plenary Sessions – The Elgar Concert Hall	Location Speaker
8:15–9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–11:00	Session 5: Design and Delivery of Novel Therapies	
9:00 – 9:25	Keynote Lecture: Tailoring Therapy in Recurrent GBM Using Personalized Assay Platforms	Prof Soma Sengupta
9:25–9:45	An AAV-1 mediated dual-payload gene therapy for high grade glioma	Dr Faye Robinson
09:45–09:50	Power Pitch 18: TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial	Dr Gerben Borst
09:51–09:56	Power Pitch 27: Development of Precision Virotherapies for Diffuse Midline Gliomas	Ms Mariana Varela Pereira
09:57–10:02	Power Pitch 150: The Value of Early Biological Information in Glioblastoma Drug Development: A Health Economic Evaluation of Window-of-Opportunity Trials	Dr Melyda Melyda
10:03–10:33	Platinum Sponsored talk	Northwest Bio
10:33–11:00	Refreshments & Exhibition	Aston Webb Great Hall
11:00–12:45	Plenary Session 6	
11:00–11:25	Keynote lecture: NIHR Consortium	Prof Juanita Lopez
11:25–11:32	Free Paper 51: Does it matter where you are treated? Insights from a national review of NHS brain tumour services (2020–2026)	Mr Andrew Wright
11:33–11:40	Free Paper 36: The cost of a brain tumour: The Economic Case for Urgent Action	Clair Thorstensen-Woll
11:45–12:30	BNOS Future Strategy Discussion	
12:30–12:35	BNOS 2027	
12:35–12:45	Closing remarks	Prof Andrew Brodbelt
12:45 – 14:00	Departure lunch and exhibition	Aston Webb Great Hall
13:00–14:00	BNOS Council Meeting	

14:00 – 16:00	Student and trainee committee: Updates in Advanced Diagnostics and Therapeutics in Neuro-oncology	The Elgar Concert Hall
14:00 – 14:30	Neuroimaging advances	
14:30 – 15:00	Neuropathology bootcamp	
15:00 – 15:30	Radiotherapy frontiers	
15:30 – 16:00	Targeted therapies in neuro-oncology	

	Parallel Sessions – Aston Webb C Block Lecture Theatre	Location Speaker
8:15 – 9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:00	Session 5: Parallel session: Global Neuro–Oncology	Aston Webb C Block Lecture Theatre
9:00 – 9:25	Neuro–Oncology in Gaza	Mr Ismail Urgratdhar
9:26 – 9:36	Neuro–Oncology in Nepal	Dr Deependra Simangainda
9:36 – 9:46	Neurosurgical Oncology in Ethiopia	Dr Salahadin Mohammed
09:47–09:57	Top scoring abstract 130: Delivering Global Skull Base Education By WhatsApp – Experience From The January 2025 Vestibular Schwannoma Challenge.	Dr Dilaxiha Rajendran
10:30–11:00	Refreshments & Exhibition	Aston Webb Great Hall
12:45 – 14:00	Departure lunch and exhibition	Aston Webb Great Hall

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers (unless declared on the programme) and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.